Fig 1.
Amplification and sequencing of RET/PTC variants.
The qRT-PCR amplification curves show amplification of RET/PTC1, 2 and 3 (red curves) and GAPDH control (green curve). (A) Tumor with the RET/PTC1 fusion gene. (B) Tumor without the RET/PTC2 fusion gene. (C) Tumor without the RET/PTC3 fusion gene (D) DNA sequencing analysis of PCR products containing RET/PTC1. (E) DNA sequencing analysis of PCR products containing RET/PTC2. (F) DNA sequencing analysis of PCR products containing RET/PTC3.
Table 1.
Association between RET/PTC rearrangement and pathological parameters in thyroid cancer patients.
Table 2.
Association between RET/PTC rearrangement and lifestyle of patients with thyroid cancer.
Table 3.
Association between RET/PTC rearrangements and thyroid function in all thyroid cancer patients.
Table 4.
Association between RET/PTC rearrangement and thyroid function in thyroid cancer patients without nodular goiter or Hashimoto's thyroiditis.
Table 5.
Association between RET/PTC rearrangements and changes in thyroid function in thyroid cancer patients.